BACKGROUND
Limited population-based analyses of associations of comorbid depression and diabetes have tested metabolic risk factors as mediating variables for the association between depression and clinical outcomes.
METHODOLOGY
We included Chinese adults with type 2 diabetes attending structured diabetes risk assessment in Hong Kong between 1 January 2000 and 30 June 2024. Depression was identified using International Classification of Disease-9 codes or prescription of anti-depressants. People with baseline cardiovascular disease or end-stage kidney disease (ESKD) were excluded. We estimated the hazard ratio (HR) of cardiovascular diseases, ESKD, all-cause death associated with depression compared to those without depression. We examined the mediating effects of eight cardiometabolic risk factors in these risk associations.
RESULTS
Among 571,129 people with type 2 diabetes, 7.5% had depression (mean age 60.4 years, 66.1% women, mean HbA1c 7.2%). People with depression had greater number of all-cause hospitalisation and longer length of stay. Compared to no depression, depression was associated with higher hazards for incident cardiovascular disease (HR: 1.21 [1.17, 1.24]), all-cause death (HR: 1.30 [1.26, 1.33]), but not ESKD (HR 0.95 [0.89, 1.01]), adjusted for age, sex and diabetes duration. Mediation analyses revealed the association between depression, cardiovascular disease and all-cause death were mediated predominantly by the direct effect of depression.
CONCLUSION
Depression is associated with greater risks for incident cardiovascular disease and all-cause death in people with type 2 diabetes. Mediation analyses revealed minor contributions from metabolic risk factors on these associations, highlighting the need for enhanced screening for depression and integrated care.
Edith W. K. Chow, E. Lau, Hongjiang Wu et al.· Journal of Affective Disorde...· 0 citations
BACKGROUND AND AIMS
Metabolic dysfunction-associated steatotic liver disease (MASLD) is strongly associated with dyslipidemia, which is a major risk factor for cardiovascular diseases and the leading cause of mortality in MASLD. This study aimed to compare the low-density lipoprotein cholesterol (LDL-C) response to statins in patients with and without hepatic steatosis.
METHODS
We identified subjects from a population screening program for MASLD who were subsequently started on statins. Statin response was defined as the absolute decrease between prestatin LDL-C level and LDL-C levels from months 0 to 3 and from months 3 to 12, modelled using multivariable linear mixed models.
RESULTS
Among 922 subjects who underwent proton-magnetic resonance spectroscopy screening, 286 received statin during follow-up, among whom 132 (46%) had hepatic steatosis (liver fat fraction ≥ 5%) at baseline. The mean defined daily dose of statins was 0.50 ± 0.32 units. The analysis on LDL-C average change per month over 12 months revealed no significant association between hepatic steatosis and statin response. Hepatic steatosis showed a nonsignificant association with poorer statin response over months 0-3 (difference of 0.097 mmol/L per month vs. no hepatic steatosis, p = 0.231) and months 3-12 (-0.037 mmol/L per month, p = 0.141), which remained after adjusting for diabetes, BMI, defined daily dose of statin, use of other lipid-lowering drugs, age, and sex.
CONCLUSIONS
The association between hepatic steatosis and poorer LDL-C response to statins, if any, is not clinically significant. Patients with hepatic steatosis are recommended to receive a standard statin dose according to clinical indications.
Kristopher Cho-Hei Lau, V. W. Wong, Alice P. S. Kong et al.· Journal of Gastroenterology...· 0 citations